Summary of the 2005 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 978-982

  Ward, Michael M ^a   Bruckel, Jane ^b   Colbert, Robert ^c   Deodhar, Atul ^d   Emerson, Christopher ^b   Genant, Harry ^e   Gladman, Dafna D ^f   Inman, Robert ^f   Reveille, John D ^g   Sandborg, Christy ^h   Weisman, Michael H ⁱ   Davis Jr , John C ^e  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b Spondylitis Association of America   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; GENETIC ANALYSIS; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SACROILIITIS; SPONDYLITIS;

BIOMEDICAL RESEARCH; CHILD; HUMANS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 33646446431     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Guidelines for the use of anti-TNF therapy in patients with ankylosing spondylitis. Sherman Oaks, CA: Spondylitis Association of America. Available at: http://www.spondylitis.org/physician_resources/guidelines.aspx. Accessed February 8, 2006
2. Colbert RA. The immunobiology of HLA-B27: variations on a theme. Curr Mol Med 2004;4:21-30.
3. Turner MJ, Sowders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005;175:2438-48.
4. Kollnberger S, Bird LA, Roddis M, et al. HLA-B27 chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 2004;173:1699-710.
5. Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: Evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001;68:916-26.
6. Zhang G, Luo J, Bruckel J, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50:2246-54.
7. Miceli-Richard C, Zouali H, Said-Nahal R, et al. Significant linkage to spondyloarthropathy on 9q31-34. Hum Mol Genet 2004;13:1642-8.
8. Tse S, Inman R, Botelho R, Chiu B, Petric M, Grinstein S. Persistence of Chlamydia in reactive arthritis: via evasion of the apoptotic pathway? J Biol Chem 2005;280:25210-15.
9. Zhang X, Glogauer M, Zhu F, Kim T, Chiu B, Inman RD. Innate immunity and arthritis: neutrophil rac and toll-like receptor 4 expression define outcomes in infection-triggered arthritis. Arthritis Rheum 2005;52:1297-304.
10. Zhang X, Aubin JE, Kim TH, Payne U, Chiu B, Inman RD. Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. Infect Immun 2004;72:7183-9.
11. Appel H, Loddenkemper C, Kuhne M, et al. Osteoclastic vasoproliferative lesions and subchondral T cell infiltrates at the bone/cartilage interface in AS patients with hip arthritis [abstract]. Ann Rheum Dis 2005;64Suppl III:108.
12. Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 2005;7:R513-25.
13. Maksymowych WP, Rahman P, Reeve J, Gladman D, Peddle L, Inman RD. Association of the interleukin-1 locus with susceptibility to ankylosing spondylitis: a Spondyloarthritis Research Consortium of Canada (SPARCC) analysis of 3 Canadian populations. Arthritis Rheum, in press.
14. Park M, Lee S, Park Y, Lee S. Correlations of serum bone morphogenetic proteins and TFG-β levels with spinal dysmobility and radiographic damage in ankylosing spondylitis [abstract]. Ann Rheum Dis 2005;64Suppl III:312.
15. Grigoryan M, Roemer FW, Mohr A, Genant HK. Imaging in spondyloarthropathies. Curr Rheumatol Rep 2004;6:102-9.
16. Taylor WJ, Helliwell PS, Gladman DD, Mease P, Mielants M, Marchesoni A. A validation of current classification criteria for the diagnosis of psoriatic arthritis -preliminary results of the CASPAR study [abstract]. Ann Rheum Dis 2005;64 Suppl III:107.
17. Stone MA, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset AS. Arthritis Rheum 2005;53:445-51.
18. Podbielski D, Bruckel J, Warren R, et al. Validation of a self assessment spinal deformity tool for ankylosing spondylitis. Arthritis Rheum, in press.
19. Ward MM, Weisman MH, Davis JC Jr, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005;53:710-7.
20. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2005 Sep 15; [Epub ahead of print].
21. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2005 Sep 15; [Epub ahead of print].
22. Braun J, Pham T, Sieper J, et al. ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
23. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2005 Nov 24; [Epub ahead of print].
24. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31:390-2.
25. Tse SM, Burgos-Vargas R, Laxer RM. Anti tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 2005;52:2103-8.
26. Maksymowych WP, Inman RD, Gladman D, et al, for the Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003;30:1356-63.